Shijiazhuang Yiling Pharmaceutical Co.,Ltd.(002603),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

002603 Shijiazhuang Yiling Pharmaceutical Co.,Ltd.

Closed 12-12 15:00:00

17.49

-0.17

-0.96%

High17.69	Low17.30	Vol26.86M
Open17.59	D1 Closing17.66	Amplitude2.21%
Mkt Cap29.23B	Tradable Cap24.08B	Total Shares1.67B
T/O470.00M	T/O Rate1.95%	Tradable Shares1.38B
P/B2.76	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","latestPrice":17.49,"timestamp":1765523013000,"preClose":17.66,"halted":0,"volume":26861278,"delay":0,"changeRate":-0.0096,"floatShares":1377000000,"shares":1671000000,"eps":-0.167,"marketStatus":"Closed","change":-0.17,"latestTime":"12-12 15:00:00","open":17.59,"high":17.69,"low":17.3,"amount":470000000,"amplitude":0.0221,"askPrice":17.5,"askSize":10,"bidPrice":17.49,"bidSize":7813,"shortable":0,"etf":0,"ttmEps":-0.167,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":17.66,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":19.43,"lowLimit":15.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.76,"roa":"--","roe":"9.34%","epsLYR":-0.4337,"committee":0.948097,"marketValue":29221000000,"turnoverRate":0.0195,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-12-15.","floatMarketCap":24081000000},"requestUrl":"/m/hq/s/002603/tweets","defaultTab":"tweets","newsList":[{"id":"2589865293","title":"Yiling Pharmaceutical's Qifang Bitong Tablets Placed in China's Insurance Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865293","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865293?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:30","pubTimestamp":1765168257,"startTime":"0","endTime":"0","summary":"Shijiazhuang Yiling Pharmaceutical  said qifang bitong tablets, developed by subsidiary Beijing Yiling Pharmaceutical, were included in China's National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List, according to a Shenzhen bourse filing on Monday.The new list will be effective from Jan. 1, 2026, to Dec. 31, 2027.The drug is used to treat persistent allergic rhinitis.The pharmaceutical company's shares slipped over 1% during the midday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0042","BK0046","BK0188","BK0097","BK0239","002603"],"gpt_icon":0},{"id":"1131023914","title":"Six Traditional Chinese Medicines Added to National Reimbursement Drug List, with Products from Kanion, Yiling, Sanjiu, and Fangsheng Included","url":"https://stock-news.laohu8.com/highlight/detail?id=1131023914","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131023914?lang=en_us&edition=fundamental","pubTime":"2025-12-08 11:50","pubTimestamp":1765165845,"startTime":"0","endTime":"0","summary":"At the 2025 High-Quality Development Conference for Innovative Drugs held yesterday, the updated National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0042","BK0060","BK0239","BK0012","BK0188","603998","600557","BK0028","BK0196","000999","BK0046","BK0010","BK0185","002603","BK0175","BK0183","BK0097"],"gpt_icon":0},{"id":"1128170178","title":"Yiling Pharmaceutical's Subsidiary's Exclusive Product Qifang Bitong Tablets Included in National Reimbursement Drug List for First Time","url":"https://stock-news.laohu8.com/highlight/detail?id=1128170178","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128170178?lang=en_us&edition=fundamental","pubTime":"2025-12-07 23:04","pubTimestamp":1765119854,"startTime":"0","endTime":"0","summary":"On the evening of December 7, Shijiazhuang Yiling Pharmaceutical Co., Ltd. announced that Qifang Bitong Tablets, an exclusive product of its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co.,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002603","BK0097","BK0188","BK0046","BK0042"],"gpt_icon":0},{"id":"2586678515","title":"Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2586678515","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586678515?lang=en_us&edition=fundamental","pubTime":"2025-11-28 18:29","pubTimestamp":1764325770,"startTime":"0","endTime":"0","summary":"Shijiazhuang Yiling Pharmaceutical (SHE:002603) subsidiary Beijing Yiling has withdrawn its drug registration application for Chaihuang Lidan capsules after receiving approval from China's drug regula","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0042","002603","BK0188","BK0097","BK0046","BK0239"],"gpt_icon":0},{"id":"2583559834","title":"Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559834","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583559834?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:28","pubTimestamp":1763018934,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved the marketing application for the memantine hydrochloride chemical raw material made by Shijiazhuang Yiling Pharmaceutical  subsidiary Wanyang Hengshui Pharmaceutical.The drug treats moderate to severe dementia from Alzheimer's disease by blocking neuron damage due to high glutamate levels, according to a Thursday filing with the Shenzhen bourse.Shares closed 2% higher on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0046","BK0042","BK0239","BK0188","BK0097","002603"],"gpt_icon":0},{"id":"1126379899","title":"Shijiazhuang Yiling Pharmaceutical (002603.SZ) Obtains Approval for Memantine Hydrochloride API Marketing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1126379899","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126379899?lang=en_us&edition=fundamental","pubTime":"2025-11-12 16:28","pubTimestamp":1762936105,"startTime":"0","endTime":"0","summary":"Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd. (\"Hengshui Wanyang\"), recently received the \"Chemical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0046","002603","BK0188","BK0042","BK0097"],"gpt_icon":0},{"id":"1101385084","title":"Yiling Pharmaceutical Reports 80% Net Profit Growth in First Three Quarters, with 544 Million Yuan R&D Investment Showcasing \"Innovation-Driven Growth\" Model","url":"https://stock-news.laohu8.com/highlight/detail?id=1101385084","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101385084?lang=en_us&edition=fundamental","pubTime":"2025-10-28 16:11","pubTimestamp":1761639098,"startTime":"0","endTime":"0","summary":"On the evening of October 27, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Yiling Pharmaceutical) released its Q3 2025 report. During the reporting period, the company achieved revenue of 5.868...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002603","BK0042","BK0188","BK0239","BK0046","BK0097"],"gpt_icon":0},{"id":"1186057920","title":"Shijiazhuang Yiling Pharmaceutical Reports 1264.61% YoY Net Profit Growth in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1186057920","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186057920?lang=en_us&edition=fundamental","pubTime":"2025-10-27 21:20","pubTimestamp":1761571224,"startTime":"0","endTime":"0","summary":"On the evening of October 27, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Yiling Pharmaceutical) released its third-quarter report for 2025. The company reported operating revenue of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0188","BK0097","002603","BK0042","BK0239"],"gpt_icon":0},{"id":"2578613583","title":"BRIEF-Yiling Pharmaceutical Q3 Net Profit Up 1264.6% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2578613583","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578613583?lang=en_us&edition=fundamental","pubTime":"2025-10-27 16:24","pubTimestamp":1761553498,"startTime":"0","endTime":"0","summary":"BRIEF-Yiling Pharmaceutical Q3 Net Profit Up 1264.6% Y/YOct 27 (Reuters) - Shijiazhuang Yiling Pharmaceutical Co Ltd 002603.SZ:SAYS Q3 NET PROFIT UP 1264.6% Y/YSource textFurther company coverage: 002603.SZ (Reporting by Beijing Newsroom) ((Xiuhao.Chen@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nL4N3W80IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0097","BK0046","002603","BK0042","BK0239"],"gpt_icon":0},{"id":"2578133716","title":"Yiling Pharmaceutical  Says Q3 Net Profit up 1264.6% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2578133716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578133716?lang=en_us&edition=fundamental","pubTime":"2025-10-27 16:24","pubTimestamp":1761553498,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nL4N3W80IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0042","BK0097","BK0239","BK0046","002603","BK0188"],"gpt_icon":0},{"id":"1107708944","title":"Shijiazhuang Yiling Pharmaceutical's First-Half Profit Growth Continues as \"R&D-Driven Growth\" Reshapes Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=1107708944","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107708944?lang=en_us&edition=fundamental","pubTime":"2025-08-29 11:50","pubTimestamp":1756439442,"startTime":"0","endTime":"0","summary":"On the evening of August 27, Shijiazhuang Yiling Pharmaceutical Co.,Ltd. released its 2025 interim report. Core profitability indicators showed comprehensive improvement: the company achieved...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002603","BK0042","BK0188","BK0046","BK0097","BK0239"],"gpt_icon":0},{"id":"2562713178","title":"BRIEF-Shijiazhuang Yiling Pharmaceutical H1 Net Profit Up 26.0% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2562713178","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562713178?lang=en_us&edition=fundamental","pubTime":"2025-08-27 16:18","pubTimestamp":1756282733,"startTime":"0","endTime":"0","summary":"BRIEF-Shijiazhuang Yiling Pharmaceutical H1 Net Profit Up 26.0% Y/YAug 27 (Reuters) - Shijiazhuang Yiling Pharmaceutical Co Ltd 002603.SZ:H1 NET PROFIT UP 26.0% Y/YSource textFurther company coverage: 002603.SZ (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nL4N3UJ0H0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0046","BK0042","BK0097","002603","BK0239"],"gpt_icon":0},{"id":"2550813969","title":"Yiling Pharmaceutical Receives Regulatory Greenlight for Review of Banxia Baizhu Tianma Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2550813969","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550813969?lang=en_us&edition=fundamental","pubTime":"2025-07-11 15:33","pubTimestamp":1752219191,"startTime":"0","endTime":"0","summary":"Shijiazhuang Yiling Pharmaceutical (SHE:002603) received review acceptance from China's medical products administrator for its Banxia Baizhu Tianma granules.The product targets conditions such as dizziness, nausea and phlegm-wind syndrome, according to a Friday filing with the Shenzhen bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0046","BK0239","BK0042","BK0097","002603"],"gpt_icon":0},{"id":"2549561590","title":"Yiling Pharmaceutical Gets Nod to Trial G201-Na Capsule","url":"https://stock-news.laohu8.com/highlight/detail?id=2549561590","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549561590?lang=en_us&edition=fundamental","pubTime":"2025-07-08 14:46","pubTimestamp":1751957210,"startTime":"0","endTime":"0","summary":"Shijiazhuang Yiling Pharmaceutical  will conduct clinical trials on the G201-Na capsule after obtaining approval from China's National Medical Products Administration, according to a Shenzhen bourse filing on Tuesday.The drug will be tested for the prevention of premature ovulation in patients undergoing controlled ovarian hyperstimulation during assisted reproductive technology.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002603","BK0042","BK0188","BK0046","BK0097","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","stockEarnings":[{"period":"1week","weight":-0.0385},{"period":"1month","weight":-0.1259},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.2256},{"period":"1year","weight":0.0088},{"period":"ytd","weight":0.1115}],"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","perCapita":"9013股","boardName":"医药制造业","registeredCapital":"167070万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊和芪苈强心胶囊。公司先后多次承担国家及省部级科研计划项目，荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","serverTime":1765713019586,"listedPrice":34.56,"stockholders":"152746人(较上一季度减少10.22%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.(002603),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shijiazhuang Yiling Pharmaceutical Co.,Ltd.(002603) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.,002603,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票老虎,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票老虎国际,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.行情,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票行情,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股价,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股市,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票价格,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票交易,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票购买,Shijiazhuang Yiling Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.(002603),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shijiazhuang Yiling Pharmaceutical Co.,Ltd.(002603) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction